Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Evrysdi
Pharma
Biogen bets HD Spinraza can outmuscle Roche's oral rival
Biogen recorded declining sales for Spinraza throughout 2025 but sees positive signs with the launch of its high-dose version of the drug in Japan.
Kevin Dunleavy
Feb 6, 2026 12:02pm
Roche picks up FDA nod for easier Evrysdi dosing format in SMA
Feb 12, 2025 2:30pm
Roche files patent suit to fend off potential Evrysdi generics
Nov 20, 2024 9:44am
Biogen reports promising results for higher dose of Spinraza
Oct 9, 2024 7:30am
Biogen to seek approval for high-dose version of Spinraza
Sep 4, 2024 11:45am
Royalty commits up to $1.5B for most of PTC's Evrysdi royalties
Oct 19, 2023 11:13am
